Abstracts tagged "methotrexate (MTX)"

Abstract Number: 609 • 2015 ACR/ARHP Annual Meeting
A Reduction in Serum Uric Acid Levels May be Related to Methotrexate Efficacy in Early Rheumatoid Arthritis: Data from a Canadian Arthritis Cohort
Jason Lee¹, VP Bykerk², George Dresser³, Gilles Boire⁴, Boulos Haraoui⁵, Carol Hitchon⁶, J Carter Thorne², Diane Tin⁷, Shahin Jamal⁸, Edward C. Keystone⁹, Janet E. Pope¹⁰ and CATCH Investigators, ¹Rheumatology, Western University, St. Joseph's Hospital, London, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Clinical Pharmacology and Toxicology, Western University, London, ON, Canada, ⁴Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Institut de Rhumatologie, Montreal, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸Vancouver Coastal Health, Vancouver, BC, Canada, ⁹Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁰Monsignor Roney Bldg/Rheum, University of Western Ontario, St Joseph Health Care, London, ON, Canada
Background/Purpose: The mechanism of methotrexate in rheumatoid arthritis (RA) is complex. It may increase adenosine levels by blocking conversion to of xanthine to uric acid…
Abstract Number: 3194 • 2015 ACR/ARHP Annual Meeting
Oral to Subcutaneous Methotrexate Dose-Conversion Strategies in the Treatment of Rheumatoid Arthritis
Michael Schiff¹ and Peter Sadowski², ¹Division of Rheumatology, University of Colorado, Denver, CO, ²Antares Pharma Inc., Minneapolis, MN
Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) therapy1 but absorption saturation limitations compromise oral MTX bioavailability (BA). Subcutaneous (SC) MTX has a…
Abstract Number: 1024 • 2015 ACR/ARHP Annual Meeting
Disruptions in Folate Homeostasis May Lead to Increased Risk for Methotrexate Intolerance in Juvenile Idiopathic Arthritis
Mara L Becker¹, Leon van Haandel², Ryan Funk³, Rodger Gaedigk⁴ and J.S. Leeder⁵, ¹Rheumatology, Children's Mercy Kansas City, Kansas City, MO, ²Clinical Pharmacology, Medical Toxicology, and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, MO, ³University of Kansas Medical Center, Kansas City, KS, ⁴Clinical Pharmacology, medical Toxicology and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, MO, ⁵Clinical Pharmacology, Medical Toxicology and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, MO
Background/Purpose: Despite widespread use, there remain no clear predictors of methotrexate (MTX) response or toxicity in Juvenile Idiopathic Arthritis (JIA). With the utilization of new…
Abstract Number: 3197 • 2015 ACR/ARHP Annual Meeting
Clinical Practice Experience in Rheumatoid Arthritis Patients Treated with Triple Therapy and Methotrexate-Tumor Necrosis Factor Inhibition Differs from That of Randomized Controlled Trials
Daniel Erhardt¹, Brian Sauer², Chia-Chen Teng³, Ted R. Mikuls⁴, Jeffrey R. Curtis⁵, Derek Tang⁶, Bradley S. Stolshek⁶ and Grant W. Cannon¹, ¹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Recently published randomized controlled trials (RCTs) have demonstrated similar outcomes in rheumatoid arthritis (RA) patients treated with triple therapy [methotrexate (MTX), sulfasalazine (SUL) and…
Abstract Number: 1039 • 2015 ACR/ARHP Annual Meeting
The Safety and Effect on Disease Activity of Tocilizumab in Combination with MTX Versus Tocilizumab Monotherapy in Patients with Mild to Moderate RA: An Attempt to Optimise the Treatment Response
Burkhard Leeb^1,2, Raimund Lunzer³, Peter Fasching⁴, Manfred Herold⁵, O. Zamani⁶, Winfried Graninger⁷ and OPTIMISE trial Investigators, ¹2nd Dept. of Medicine, State Hospital Stockerau, Center for Rheumatology Lower Austria, Stockerau, Austria, ²Department of Clinical Rheumatology, Karl Landsteiner Society, Stockerau, Austria, ³Department of Internal Medicine, Hospital Barmherzige Brüder Graz-Eggenberg, Graz, Austria, ⁴Department of Internal Medicine V, Wilhelminen Hospital Vienna, Vienna, Austria, ⁵Internal Medicine VI, Medical University of Innsbruck, Austria, Innsbruck, Austria, ⁶Rheumazentrum Favoriten, Wien, Austria, ⁷Rheumatology and Immunology, Medical University of Graz, Graz, Austria
Background/Purpose: An Austrian multi-center study of the effect on disease activity and the safety of Tocilizumab (TCZ) in combination with Methotrexate (MTX) versus TCZ Monotherapy…
Abstract Number: 3239 • 2015 ACR/ARHP Annual Meeting
Response to Methotrexate Predicts Mortality in Rheumatoid Arthritis up to 30 Years
Carolin Krause¹, Siegfried Wassenberg², Rolf Rau³, Gertraud Herborn⁴, Juergen Braun⁵ and Dietmar Krause⁶, ¹University Munster, Munster, Germany, ²Rheumaklinik, Themistocles Gluck hospital - Rheumazentrum Ratingen, Ratingen, Germany, ³Expert in Rheumatology, Düsseldorf, Germany, ⁴Evangelisches Fachkrankenhaus Ratingen, Ratingen, Greece, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶Dept. for Medical Informatics, Biometry and Epidemiology, Ruhr University, Bochum, Germany
Background/Purpose: Methotrexate (MTX) is considered as the anchor drug for the treatment of patients with rheumatoid arthritis (RA). MTX has been shown to reduce disease…
Abstract Number: 1041 • 2015 ACR/ARHP Annual Meeting
Methotrexate Monotherapy and Methotrexate Combination Therapy with Traditional and Biologic Dmards for Rheumatoid Arthritis: A Cochrane Systematic Review and Network Meta-Analysis
Glen S. Hazlewood^1,2, Cheryl Barnabe³, George A. Tomlinson⁴, Deborah Marshall⁵, Daniel Devoe⁵ and Claire Bombardier⁶, ¹Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶18 Strathearn Blvd, University of Toronto, Toronto, ON, Canada
Background/Purpose: To compare methotrexate based disease-modifying anti-rheumatic drug (DMARD) treatments for rheumatoid arthritis in patients naïve to or after an inadequate response (IR) to methotrexate. …
Abstract Number: 3247 • 2015 ACR/ARHP Annual Meeting
Dietary Intake of Omega-3 Fatty Acids and Vitamin C and D Associate with Decreased Pain, Independent of Inflammation, in MTX Treated Early RA Patients
Cecilia Lourdudoss¹, Alicja Wolk², Lars Alfredsson³, Lars Klareskog⁴, Ronald F. van Vollenhoven⁵ and Jon Lampa⁶, ¹Dept. of Medicine, ClinTRID, Karolinska institutet, Stockholm, Sweden, ²Institute of Environmental Medicine (IMM), Karolinska institutet, Stockholm, Sweden, ³The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Karolinska University Hospital, Stockholm, Sweden, ⁵Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ⁶Dep of Medicine, Rheumatology unit, Karolinska Institute, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Chronic pain is common in RA and considered as the major disease burden from the patients’ perspective. Earlier data suggest that omega-3 fatty acids,…
Abstract Number: 1044 • 2015 ACR/ARHP Annual Meeting
Many Patients with Early Rheumatoid Arthritis Want Triple Therapy: An Analysis Combining Comparative Effectiveness Research and Patients Preferences to Inform Treatment Recommendations
Glen S. Hazlewood^1,2, Claire Bombardier³, George A. Tomlinson⁴ and Deborah Marshall⁵, ¹Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴Medicine, University Health Network, Toronto, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada
Background/Purpose: Growing evidence supports the efficacy of triple therapy (methotrexate + sulphasalazine + hydroxychloroquine) for controlling disease activity in patients with early rheumatoid arthritis (ERA),…
Abstract Number: 1577 • 2015 ACR/ARHP Annual Meeting
Periodontal Evaluation Is Associated with Increased Likelihood of Achieving Low Disease Activity in Rheumatoid Arthritis with Methotrexate
Melanie Rohr¹, James R. O'Dell¹, Abhijeet Danve², Harlan Sayles¹, Geoffrey M. Thiele³, Jeffrey Payne⁴ and Ted R. Mikuls⁵, ¹University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Research Services 151, Omaha VA Medical Center, Omaha, NE, ⁴College of Dentistry, University of Nebraska Medical Center, Lincoln, NE, ⁵Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) outcomes have improved substantially due to the development of new drug therapies, but also due to emphasis on early aggressive MTX…
Abstract Number: 1632 • 2015 ACR/ARHP Annual Meeting
Do RA Susceptibility Loci Predict Response to Methotrexate As First DMARD in Early RA?
Thomas Frisell¹, Saedis Saevarsdottir^2,3 and Johan Askling^1,4, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Improved means to predict which RA patients will respond to methotrexate monotherapy, the preferred first line therapy in early RA, would allow patients to…
Abstract Number: 1640 • 2015 ACR/ARHP Annual Meeting
Effect of Methotrexate Dose on the Efficacy of Tofacitinib: Treatment Outcomes from a Phase 3 Clinical Trial of Patients with Rheumatoid Arthritis
Roy Fleischmann¹, Philip J. Mease², Sergio Schwartzman³, Lie-Ju Hwang⁴, Aditya Patel⁵, Koshika Soma⁴, Carol A. Connell⁶, Liza Takiya⁴ and Eustratios Bananis⁷, ¹Rheumatology, Metroplex Clinical Research Center, Dallas, TX, ²Rheumatology Research, Swedish Medical Center, Seattle, WA, ³Hospital for Special Surgery, New York, NY, ⁴Pfizer Inc, New York, NY, ⁵Inventiv Health Inc, South Plainfield, NJ, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). ORAL Scan was a 2-year, randomized, Phase 3, clinical trial…
Abstract Number: 1997 • 2015 ACR/ARHP Annual Meeting
Underuse of Methotrexate (MTX) in the Treatment of Rheumatoid Arthritis (RA) in the United States (US): Results of a Comprehensive Pharmaceutical Claims Analysis
James R. O'Dell¹, Melanie Rohr¹, Stanley B. Cohen², J Carter Thorne³ and Ted R. Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Metroplex Clinical Research Center, Dallas, TX, ³Southlake Regional Health Centre, Newmarket, ON, Canada
Background/Purpose: MTX is the anchor DMARD for RA treatment, but there is limited information about its appropriate use in clinical practice. This claims analysis was…
Abstract Number: 2138 • 2015 ACR/ARHP Annual Meeting
Safety and Efficacy Results of a Phase 2, Double-Blind, Placebo-Controlled Clinical Study of Duvelisib with Background Methotrexate (MTX) in Adults with Moderate-to-Severe Rheumatoid Arthritis (RA)
Richard Leff¹, Sunil Kumar², Natalia Nikulenkova³, Igor Kaidashev⁴, Kerstin Allen⁵, Joi Dunbar⁶, Howard Stern⁷, Julian Adams⁶ and Michael Weinblatt⁸, ¹Clinical Research, Infinity Pharmaceuticals, Inc., Cambridge, MA, ²Centre for Clinical Research and Effective Practice (CCRep), Auckland, New Zealand, ³State Budgetary Healthcare Institution of Vladimir Region, Regional Clinical Hospital, Vladimir, Russia, ⁴City Clinical Hospital #1 of Poltava City, Poltava, Ukraine, ⁵Biostatistics, Infinity Pharmaceuticals, Inc., Cambridge, MA, ⁶Infinity Pharmaceuticals, Inc., Cambridge, MA, ⁷Translational Science, Infinity Pharmaceuticals, Inc., Cambridge, MA, ⁸Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Duvelisib is a potent, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-δ,γ being developed for hematologic malignancies, and was also explored in early phase studies in…
Abstract Number: 187 • 2015 ACR/ARHP Annual Meeting
Detection of Power Doppler Ultrasound Signals in Rheumatic Diseases Using Superb Microvascular Imaging (SMI): Comparison with Conventional Power Doppler Ultrasound
Kazuhiro Yokota¹, Takuma Tsuzuki Wada², Yuji Akiyama² and Toshihide Mimura³, ¹Department of Rheumatology & Applied Immunology, Faculty of Medicine, Saitama Medical University, Irama, Japan, ²Department of Rheumatology & Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma, Japan, ³Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: The detection of power Doppler (PD) ultrasound signals in joints may be considered as the presence of joint inflammation, i.e., synovitis which is a…

« Previous Page
1
…
7
8
9
10
11
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.